Tectonic Therapeutic Inc

CEO’s bulk RSU purchase shows Tectonic Therapeutic insiders trust the gene‑therapy pipeline, boosting investor confidence and potential upside.

CEO insider buy at $21.10 shows confidence in Tectonic Therapeutics’ single‑dose gene therapy pipeline and signals potential upside for investors.

CEO Reicin Alise’s recent buy of 2,500 Tectonic Therapeutic shares at $21.10—below market and 52‑week lows—signals insider confidence in the company’s gene‑therapy pipeline, offering investors insight into strategic repositioning amid market volatil…

Lochner Daniel’s $21.61 buy of 6,000 shares shows quiet confidence in Tectonic’s pipeline—insider buying paired with rising social buzz may signal near‑term upside for the biotech stock.